Anti-BRAFV600E antibody [IHC600] (STJA0042070)
SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgG2b
General Information
| Short Description | Mouse monoclonal anti-BRAFV600E for use in IHC-p in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-p |
| Host | Mouse |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | IHC600 |
| Isotype | IgG2b |
| Conjugation | Unconjugated |
| Dilution Range | 1:50-1:200 |
| Formulation | Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide |
| Storage Instruction | Store at 2-8°C for up to 1 year. Do not freeze. |
Target Information
| Specificity | Tested and validated on colorectal adenocarcinoma, thyroid papillary carcinoma with the braf v600e mutation tissue. |
Additional Info
| Background | Serine/Threonine-Protein Kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family, which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway. Oncogenic mutations in the BRAF gene, 80% of which are a single V600E substitution within the kinase domain, constitutively activate the MAPK signaling pathway and result in increased cell proliferation and apoptosis resistance. The V600E mutation is observed in colorectal cancer, non-Hodgkin s lymphoma, papillary thyroid carcinoma, malignant melanoma, non-small-cell lung carcinoma, and lung adenocarcinoma. BRAF V600E is therefore an important immunohistochemical marker for tumour diagnosis and prognosis. |
Information sourced from Uniprot.org